Belépés

NCT07357974Toborzás még nem indult1/2. fázis

Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH

Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH: a Pilot Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 16.

Rövid összefoglaló (regiszter, angolul)

Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by structural changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and elevated pulmonary arterial pressure and, if untreated, right heart failure. Diagnosis requires a comprehensive evaluation, including right heart catheterization performed in specialized centers. Despite advances in the understanding and management of the disease, PAH remains a severe condition. Current approved therapies primarily target three key pathways involved in endothelial dysfunction: the endothelin, nitric oxide, and prostacyclin pathways. Pulmonary arterial remodeling is characterized by alterations in endothelial cells, smooth muscle cells, and fibroblasts, with fibroblast activation and macrophage involvement contributing to disease progression. Two positron emission tomography/computed tomography (PET/CT) imaging approaches are currently under investigation in PAH. \[⁶⁸Ga\]Ga-FAPI PET/CT targets activated fibroblasts and enables noninvasive assessment of fibroblast activity and tissue remodeling. \[⁶⁸Ga\]Ga-MAA lung perfusion PET/CT is an emerging imaging technique that provides higher spatial resolution and sensitivity than conventional lung perfusion imaging and allows evaluation of regional pulmonary perfusion. Sotatercept is a novel fusion protein that modulates signaling within the transforming growth factor-beta (TGF-β) superfamily by binding select ligands involved in vascular remodeling. Its mechanism of action is distinct from that of currently approved PAH therapies. Sotatercept has been evaluated in clinical development programs, including the PULSAR and STELLAR studies. Reported adverse events include epistaxis, dizziness, increased hemoglobin levels, and changes in blood pressure. This study is designed with the following objectives: Primary objective: To assess pulmonary vascular remodeling in patients with PAH using \[⁶⁸Ga\]Ga-FAPI PET/CT imaging. Secondary objectives: To evaluate \[⁶⁸Ga\]Ga-FAPI uptake and regional lung perfusion using \[⁶⁸Ga\]Ga-MAA lung perfusion PET/CT imaging at predefined study time points.

Állapot (regiszter)
Toborzás még nem indult
Fázis (regiszter)
1/2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
15 (tervezett)
Első benyújtás
2025. dec. 2.
Kezdés
2026. júl. 15.
Elsődleges befejezés
2028. jan. 1.
Fő szponzor
University Hospital, Brest
NCT-szám
NCT07357974

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 1/2. fázis
  • Tervezett résztvevők: 15
  • 2026. júl. 15. és az elsődleges befejezés (2028. jan. 1.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis associated PAH, pulmonary veno occlusive disease and pulmonary capillary hemangiomatosis.
  • Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept

Laborértékek

  • Hemoglobin at screening above gender-specific ULN, per local laboratory test
  • Any of the following clinical laboratory values at the Screening visit:
    • eGFR \< 30 mL/min/1.73 m2 (as defined by MDRD equation)
    • Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels \> 3 × ULN
    • Platelet count \< 50,000/mm3 (\< 50.0 × 109/L)

Egyéb

  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Pregnant or breastfeeding women

Kiket keres a vizsgálat

  • Age ≥ 18 years
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum PVR of ≥ 4 Wood units and pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of WHO PAH Group 1 in any of the following subtypes:
    • Idiopathic PAH
    • Heritable PAH
    • Drug/toxine-induced PAH
    • PAH associated with connective tissue disease
    • PAH associated with simple, congenital systemic-to- pulmonary shunts at least 1year following repair
  • Patients under bi or tri-background-therapy
  • Symptomatic PAH classified WHO FC II or III
  • Patients will be started on Sotatercept
  • Ability to adhere to study visit schedule and understand and comply with all the protocol requirement.
  • Ability to understand and provide written informed consent

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Chu Brest
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát		BrestFranciaországIsmeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.